Stocks and Finance

ONYX Pharmaceuticals

11:53 : Pharma News: Abbott Labs, Onyx Pharmaceuticals - Abbott Laboratories (ABT) has said it will license a portfolio of antioxidant inflammation modulator molecules from Reata Pharmaceuticals for $400 million.

Source : forbes-com

08:04 : The FDA says Onyx Pharmaceuticals (ONXX) hasn't conducted the necessary ... - The FDA says Onyx Pharmaceuticals (ONXX) hasn't conducted the necessary trials to get a quick review of its cancer drug carfilzomib, and instead will have to settle for a standard review period. Shares -8% premarket. Post ...

14:52 : Onyx Pharmaceuticals ([[ONXX]] +13.5%) shares spike on a report that the ... - Onyx Pharmaceuticals (ONXX +13.5%) shares spike on a report that the developer of the Nexavar kidney cancer treatment is exploring options, including a possible sale. Onyx reportedly is working with Centerview Partners to review ...

07:58 : Onyx Pharmaceuticals (ONXX) agrees to settle and dismiss all claims relate - Onyx Pharmaceuticals (ONXX) agrees to settle and dismiss all claims related to the complaint filed by Onyx against Bayer (BAYRY.PK), restructuring their partnership for developing and marketing of Nexavar tablets and entering ...